HER-2 Positive Breast Cancer Clinical Trial
— PREDIX HER2Official title:
PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Verified date | August 2020 |
Source | Karolinska University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this trial is to evaluate efficacy and toxicity of either the combination of
docetaxel, trastuzumab sc and pertuzumab (arm A) or trastuzumab emtansin (arm B). Switch of
therapy to the opposite treatment alternative is applicable in case of lack of response after
two courses of treatment, or for medical reasons under exceptional circumstances (drug
reaction, other medical conditions) at any point. After termination of the primary treatment
follow-up for five years.
A translational subprotocol is a mandatory part of the study protocol, with exception for the
use of PET-CT evaluations.
Status | Active, not recruiting |
Enrollment | 202 |
Est. completion date | February 2029 |
Est. primary completion date | February 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Written informed consent 2. Patients with breast cancer confirmed by histology, characterized by immunohistochemistry for ER, PR, HER2 and proliferation marker 3. Tumor and blood samples available. HER2 type confirmed by ISH 4. Age 18 years or older. Elderly patients in condition adequate for planned therapy 5. Primary breast cancer >20mm in diameter and/or verified lymph node metastases 6. Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled medical or psychiatric disorders 7. LVEF =55% 8. ECOG performance status 0-1 9. Primary breast cancer as defined in p. 5 plus at most 2 morphologically characterized well-defined distant metastases accessible for stereotactic radiotherapy, provided that this treatment is available Exclusion Criteria: 1. Distant metastases, including node metastases in the contralateral thoracic region or in the mediastinum 2. Other malignancy diagnosed within the last five years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix 3. Patients in child-bearing age without adequate contraception 4. Pregnancy or lactation 5. Uncontrolled hypertension, heart, liver, kidney related or other medical or psychiatric disorders |
Country | Name | City | State |
---|---|---|---|
Sweden | Dept. of Oncology, Sahlgrenska University Hospital | Göteborg | |
Sweden | Dept. of Oncology, Skåne University Hospital | Lund | |
Sweden | Dept. of Oncology, Örebro University Hospital | Örebro | Närke |
Sweden | Dept. of Oncology, Karolinska University Hospital | Stockholm | |
Sweden | Dept. of Oncology, Sundsvall Hospital | Sundsvall | |
Sweden | Dept. of Oncology, University Hospital of Umeå | Umeå | |
Sweden | Dept. of Oncology, Uppsala University Hospital | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Thomas Hatschek |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes of morphological, functional and biological characteristics of early breast cancer before and after exposure to cytotoxic and targeted treatment | Includes genomics, proteomics and other biomarker-related analyses on core biopsies and blood samples before start and after two courses of treatment, collection of tumor samples from the surgical specimen at the date of operation, blood samples in connection with annual follow-up visits and FNA and blood samples in case of recurrence. Time frame for collection of biological samples from start of preoperative treatment until 60 months of follow-up post surgery. Functional imaging using 18F-FDG PET-CT is performed at baseline and after the 2nd and 6th treatment course. | 5 years | |
Primary | Pathological objective response to primary medical treatment | Efficacy measure after 18 weeks of preoperative treatment, starting from the start of preoperative medical treatment until the date of surgery. Outcome should be received within not more than 4 weeks post surgery | At surgery | |
Secondary | Clinical/radiological objective response during neoadjuvant treatment | Clinical measurements with caliper, radiological evaluations with mammography and ultrasound, alternately MRI, within 6 weeks before start, and 14 days after 3-weekly courses 2, 4 and 6; PET-CT within 2 weeks before start, and 16 days after courses 2 and 6. Time frame for these response evaluations is between between week 4 and week 18 of preoperative treatment | During the 18-week treatment period before surgery | |
Secondary | Event-free survival | Time frame for reporting is from date of randomization until first reported event, including disease progression, documented first recurrence, first contralateral breast cancer, first cancer of other origin, or death of any cause, whatever occurs first | All events from date of randomization until follow-up to 10 years | |
Secondary | Disease-free survival | Time frame for reporting is between date of surgery and 10 years follow-up. Date of detection of metastasis will be reported within 12 months after occurence | During the follow-up to 10 years | |
Secondary | Breast cancer specific survival | Time frame for reporting is between date of surgery and 60 months follow-up. Date and cause of death will be reported within 12 months after occurence | During the follow-up to 10 years | |
Secondary | Overall survival | Time frame for reporting is between date of surgery and 10 years follow-up. Date of death will be reported within 12 months after occurence | During the follow-up to 10 years | |
Secondary | Incidence of treatment-emergent adverse events [Safety and Tolerability] | Time frame for reporting of acute side effects is from start of treatment until 30 days after termination of the treatment, totally 22 weeks. Late side effects are reported within 60 months post surgery. Cardiac toxicity is given special attention during the entire period. Echocardiograms and ECGs are performed within 6 weeks before start of treatment, after 16 weeks of treatment before surgery, and then every 3 months during postoperative treatment with trastuzumab the 1st postoperative year; thereafter every 12 months until 10 years of follow-up after surgery | During the 18-week period of treatment and until 30 days after termination and during the follow-up period up to 10 years | |
Secondary | Health Related Quality of life | Repeated assessments using EOTC QLQ-C30 and BR23 during the treatment period, before randomization and after courses 2, 4 and 6, 3 months post surgery and annually during the follow-up period up to 10 years. Time frame covers the 18-week period of preoperative treatment and 10 years follow-up period after surgery | From date of randomisation until follow-up to 5 years | |
Secondary | Frequency of breast-conserving surgery | Type of surgery is recorded at the time of surgery | At surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01305941 -
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
|
Phase 2 | |
Completed |
NCT01432223 -
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
|
Phase 2 | |
Completed |
NCT01433926 -
Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years
|
N/A | |
Recruiting |
NCT05871918 -
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
|
Phase 3 | |
Terminated |
NCT02598310 -
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT02675231 -
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT02154529 -
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01565200 -
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
|
Phase 2 | |
Completed |
NCT01340430 -
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02947685 -
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT02066532 -
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01583426 -
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
|
Phase 3 | |
Completed |
NCT01677455 -
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT01361945 -
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02326974 -
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
|
Phase 2 | |
Not yet recruiting |
NCT04644406 -
PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
|
||
Terminated |
NCT02131506 -
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
|
Phase 1 | |
Completed |
NCT00788931 -
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT02488564 -
A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT02492711 -
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
|
Phase 3 |